Micron Biomedical Celebrates the Grand Opening of Its Commercial-Scale Manufacturing Site in GeorgiaNational and local leaders across government, investors, life science industry and academia acknowledge the impact of Micron’s dissolvable vaccines and therapies on human health and economic development
Micron Biomedical Named to Fast Company’s 2026 List of World’s Most Innovative Companies for Addressing the Most Significant Bottlenecks in How Medicine is Made, Distributed and AdministeredRecognition as second most innovative smaller company across all industries highlights transformative impact on public health, impactful industry collaborations, and a novel manufacturing approach that simplifies access to treatments
Micron Biomedical Names Health Education and Empowerment Advocate, Dr. Jayne Morgan, to Board of AdvisorsRole will focus on helping to inform and build public trust in vaccine and therapy options that are delivered without injections, through dissolvable technology
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines$16M extension round led by J2 Ventures and GHIC builds on support from BARDA, CEPI, the Bill & Melinda Gates Foundation and others to simplify access to life-saving drugs
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without NeedlesU.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19CEPI grant aims to build on evidence of Micron Biomedical’s needle-free delivery of vaccines to bring CastleVax’s novel rapid-response platform to the clinic
Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in InfantsATLANTA, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced the company secured a $7.5 million grant from the Bill & Melinda Gates Foundation that brings total grant funding from the organization to $43 million.
